摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-bromophenyl)-1-pyrroline | 129540-26-7

中文名称
——
中文别名
——
英文名称
2-(2-bromophenyl)-1-pyrroline
英文别名
5-(2-bromophenyl)-3,4-dihydro-2H-pyrrole
2-(2-bromophenyl)-1-pyrroline化学式
CAS
129540-26-7
化学式
C10H10BrN
mdl
——
分子量
224.1
InChiKey
GVWPMJOLTZSVCT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    279.0±32.0 °C(Predicted)
  • 密度:
    1.45±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    12.4
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    2-(2-bromophenyl)-1-pyrrolinesodium hydroxide 、 sodium tetrahydroborate 、 PPA 、 硼烷四氢呋喃络合物 作用下, 反应 0.5h, 生成 cis-10-bromo-1,2,3,5,6,10b-hexahydro-6-<4-(methylthio)phenyl>pyrrolo<2,1-a>isoquinoline
    参考文献:
    名称:
    Pyrroloisoquinoline antidepressants. 3. A focus on serotonin
    摘要:
    A collection of hexahydropyrroloisoquinoline derivatives (1-22), which represent a class of compounds that inhibit the neuronal uptake of dopamine (DA), norepinephrine (NE), and serotonin (5-HT), was investigated in vivo for serotonin-potentiating properties in the mouse head-twitch and rat serotonin syndrome assays. The p-methylthio compound 3b (McN-5652-Z) was found to possess exceptional activity in these assays, and the activity was attributable almost exclusively to the (+)-6S,10bR enantiomer. Ten closely related analogues were synthesized, tested, and compared among themselves and with some previously prepared compounds, both in vivo and in vitro. Several trans diastereomers exhibited strong inhibition of 5-HT uptake and substantial potentiation of 5-HT, while the cis diastereomers (3a, 4a, and 10a) tested were virtually devoid of such activity. Although 3b was only moderately selective in inhibiting the uptake of 5-HT vs NE, its 10-substituted analogues 4b, 7b-9b had improved 5-HT selectivity relative to NE, to the extent of 20-25 times (150-200 times relative to DA). Of these more selective compounds (in vitro), only 4b and 7b had substantial activity in vivo. Sulfoxide 11b appeared to function as a prodrug of 3b in vivo.
    DOI:
    10.1021/jm00172a018
  • 作为产物:
    描述:
    1-(2-Bromophenyl)cyclobutane-1-carboxamide 在 [双(三氟乙酰氧基)碘]苯 作用下, 以 乙腈 为溶剂, 反应 12.0h, 以64%的产率得到2-(2-bromophenyl)-1-pyrroline
    参考文献:
    名称:
    1-吡咯啉的霍夫曼重排-环扩径反应:在2,3-二氢-1H-吡咯并[2,1-a]异喹啉鎓盐的合成中的应用
    摘要:
    用双(三氟乙酰氧基)碘苯PhI(OCOCF 3)2处理环丁烷甲酰胺,导致前者的霍夫曼重排形成1-吡咯啉,然后环丁胺中间体进行原位环扩环反应。还描述了该方法对2,3-二氢-1 H-吡咯并[2,1- a ]异喹啉鎓盐的合成的进一步阐述。
    DOI:
    10.1002/adsc.201501071
点击查看最新优质反应信息

文献信息

  • [EN] ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN<br/>[FR] DÉRIVÉS (PYRROLIDIN-2-YL)PHÉNYLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA DOULEUR
    申请人:ORGANON NV
    公开号:WO2010052198A1
    公开(公告)日:2010-05-14
    The invention relates to (pyrrolidin-2-yl)phenyl derivatives having the general Formula (I), wherein R1 is (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, or halo(C1-4)alkyloxy; R2 is H, (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, halo(C1-4)alkyloxy or halogen; R3 is H, (C1-4)alkyl or halo(C1-4)alkyl; R4 is H, (C1-4)alkyl or halo(C1-4)alkyl; R5 is H, (C1-4)alkyl or halo(C1-4)alkyl; or R4 and R5, when bonded to the same carbon atom, can together with the carbon atom form a spiro(C3-6)cycloalkyl group, optionally substituted with halogen; R6 is H, (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, halo(C1-4)alkyloxy or halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these (pyrrolidin-2-yl)phenyl derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
    该发明涉及具有通式(I)的(吡咯烷-2-基)苯基衍生物,其中R1为(C1-4)烷基,卤代(C1-4)烷基,(C1-4)烷氧基或卤代(C1-4)烷氧基;R2为H,(C1-4)烷基,卤代(C1-4)烷基,(C1-4)烷氧基,卤代(C1-4)烷氧基或卤素;R3为H,(C1-4)烷基或卤代(C1-4)烷基;R4为H,(C1-4)烷基或卤代(C1-4)烷基;R5为H,(C1-4)烷基或卤代(C1-4)烷基;或者R4和R5,当与同一碳原子结合时,可以与碳原子一起形成一个可选地被卤素取代的螺环(C3-6)环烷基基团;R6为H,(C1-4)烷基,卤代(C1-4)烷基,(C1-4)烷氧基,卤代(C1-4)烷氧基或卤素;或其药学上可接受的盐,以及包含它们的制药组合物,以及这些(吡咯烷-2-基)苯基衍生物用于治疗疼痛,如神经性疼痛或炎症性疼痛。
  • (PYRROLIDIN-2-YL)PHENYL DERIVATIVES
    申请人:Grove Simon James Anthony
    公开号:US20100113493A1
    公开(公告)日:2010-05-06
    The invention relates to (pyrrolidin-2-yl)phenyl derivatives having the general Formula I wherein R 1 is (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy, or halo(C 1-4 )alkyloxy; R 2 is H, (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy, halo(C 1-4 )alkyloxy or halogen; R 3 is H, (C 1-4 )alkyl or halo(C 1-4 )alkyl; R 4 is H, (C 1-4 )alkyl or halo(C 1-4 )alkyl; R 5 is H, (C 1-4 )alkyl or halo-(C 1-4 )-alkyl; or R 4 and R 5 , when bonded to the same carbon atom, can together with the carbon atom form a spiro(C 3-6 )cycloalkyl group, optionally substituted with halogen; R 6 is H, (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy, halo(C 1-4 )alkyloxy or halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these (pyrrolidin-2-yl)phenyl derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
    该发明涉及具有通式I的(吡咯啉-2-基)苯基衍生物,其中R1为(C1-4)烷基、卤代(C1-4)烷基、(C1-4)烷氧基或卤代(C1-4)烷氧基;R2为H、(C1-4)烷基、卤代(C1-4)烷基、(C1-4)烷氧基、卤代(C1-4)烷氧基或卤素;R3为H、(C1-4)烷基或卤代(C1-4)烷基;R4为H、(C1-4)烷基或卤代(C1-4)烷基;R5为H、(C1-4)烷基或卤代(C1-4)烷基;或者当R4和R5与同一碳原子结合时,它们可以与碳原子一起形成一个可选择地取代卤素的螺环(C3-6)环烷基基团;R6为H、(C1-4)烷基、卤代(C1-4)烷基、(C1-4)烷氧基、卤代(C1-4)烷氧基或卤素;或其药学上可接受的盐,以及含有这些(吡咯啉-2-基)苯基衍生物的药物组合物,以及这些(吡咯啉-2-基)苯基衍生物用于治疗疼痛,如神经痛或炎症性疼痛。
  • Nickel-Catalyzed Annulations of <i>ortho</i>-Haloarylimines
    作者:Srinivas Kolluru、Manvendra Singh、Bryce Gaskins、Zarko Boskovic
    DOI:10.1021/acscatal.1c03092
    日期:2021.8.20
    adjacent anti stereocenters and a free secondary amine. Spirocycles are formed from cyclic imines. We characterized the key oxidative addition intermediate and identified a major path leading to competing homocoupling products. The activation energy of oxidative addition and the rate of oxidative addition complex isomerization were determined. The sensitivity of the reaction to reaction conditions was established
    我们报告了邻卤代芳基亚胺和贫电子烯烃之间的镍催化环化反应的发现、发展和机理。该反应产生两个相邻的反立体中心和一个游离的仲胺。螺环由环状亚胺形成。我们表征了关键的氧化加成中间体,并确定了导致竞争同源偶联产物的主要途径。测定了氧化加成的活化能和氧化加成络合物异构化的速率。以定量方式建立反应对反应条件的敏感性,并介绍了该方法的范围和局限性。
  • (Pyrrolidin-2-yl)phenyl derivatives
    申请人:——
    公开号:US08188123B2
    公开(公告)日:2012-05-29
    The invention relates to (pyrrolidin-2-yl)phenyl derivatives having the general Formula I wherein R1 is (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, or halo(C1-4)alkyloxy; R2 is H, (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, halo(C1-4)alkyloxy or halogen; R3 is H, (C1-4)alkyl or halo(C1-4)alkyl; R4 is H, (C1-4)alkyl or halo(C1-4)alkyl; R5 is H, (C1-4)alkyl or halo-(C1-4)-alkyl; or R4 and R5, when bonded to the same carbon atom, can together with the carbon atom form a spiro(C3-6)cycloalkyl group, optionally substituted with halogen; R6 is H, (C1-4)alkyl, halo(C1-4)alkyl, (C1-4)alkyloxy, halo(C1-4)alkyloxy or halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these (pyrrolidin-2-yl)phenyl derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
    本发明涉及具有一般式I的(吡咯烷-2-基)苯基衍生物,其中R1为(C1-4)烷基,卤代(C1-4)烷基,(C1-4)烷氧基或卤代(C1-4)烷氧基;R2为H,(C1-4)烷基,卤代(C1-4)烷基,(C1-4)烷氧基,卤代(C1-4)烷氧基或卤素;R3为H,(C1-4)烷基或卤代(C1-4)烷基;R4为H,(C1-4)烷基或卤代(C1-4)烷基;R5为H,(C1-4)烷基或卤代(C1-4)烷基;或当与同一碳原子结合时,R4和R5可以与碳原子一起形成一个spiro(C3-6)环烷基,可选择性地被卤素取代;R6为H,(C1-4)烷基,卤代(C1-4)烷基,(C1-4)烷氧基,卤代(C1-4)烷氧基或卤素;或其药学上可接受的盐,以及包含它们的制药组合物,以及这些(吡咯烷-2-基)苯基衍生物用于治疗疼痛,如神经病理性疼痛或炎症性疼痛。
  • ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN
    申请人:N.V. Organon
    公开号:EP2356105A1
    公开(公告)日:2011-08-17
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐